论文部分内容阅读
炎性肠病(inflammatory bowel disease,IBD)包括溃疡性结肠炎(ulcerative colitis,UC)和克罗恩病(Crohn’s disease,CD),其致病原因尚不清楚。目前常用的药物治疗伴有明显不良反应而且无法完全治愈疾病。最近几年IBD基因治疗引起关注。通过抑制炎症因子基因以及上调免疫调节因子基因表达来恢复肠道细胞因子的平衡是一种有前途的治疗IBD的方法。本文简要介绍几个可以用于IBD基因治疗的分子(如TNF-α、IL-10、NF-κB和IL-22等)以及它们相应的动物临床试验结果和未来展望。
Inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn’s disease (CD), the etiology of which is unclear. At present, commonly used medical treatment with obvious adverse reactions and can not completely cure the disease. IBD gene therapy has drawn much attention in recent years. Restoring the balance of gut cytokines by inhibiting the expression of inflammatory cytokines and up-regulating the expression of immunomodulatory genes is a promising approach for the treatment of IBD. This article gives a brief overview of several clinical trials and future perspectives of molecules that can be used in the gene therapy of IBD such as TNF-α, IL-10, NF-κB and IL-22, as well as their corresponding animals.